Objectives: The aim of this study was to investigate the prophylactic effect of magnesium sulfate on the intraocular pressure in patients undergoing laparoscopic cholecystectomy. This study is a randomized, double-blind clinical trial.
Inclusion criteria: age of eighteen years and above, ASA I and II, weighting between 50 to 80 kg, patients who had been scheduled for laparoscopic cholecystectomy.
Exclusion criteria: arrhythmia, heart diseases, musculoskeletal diseases like myasthenia Grove, kidney failure, acute or chronic eye disease, history of using any drugs that affects intraocular pressure. Patients were randomly divided into two groups of intervention group who received 30 mg/kg magnesium sulfate and patients in control group received 20 cc, normal saline. Sample Size: 40 patients found eligible based on the inclusion criteria.
Interventions: The magnesium sulfate was solved in 100cc normal saline and infused within 20 minutes in the treatment group, and 100 cc normal saline was infused to patients in control group before the operation. The possibility of Magnesium toxicity was quite low with this dose but neurological examinations were done for every patient. Mean arterial blood pressure, heart rate, intraocular pressure, (paw) peak and plate airway pressure, ETCO2 were measured, continuously during the operation. Tetracaine eye drop was used before measuring intraocular pressure via Tonopen. CO2 insufflation was done in supine position and peritoneal gas pressure was maintained at 12 mmHg during the operation. Primary and secondary outcome measures were to investigate the prophylactic effect of magnesium sulfate on the intraocular pressure during laryngoscopy, intubation and CO2 insufflation.